^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    VOTRIENT is a kinase inhibitor indicated for the treatment of patients with:...advanced renal cell carcinoma (RCC).
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...non-clear cell RCC patients found treatment with pazopanib to be effective and safe...the NCCN Kidney Cancer Panel has included these therapies as a therapy option for patients with relapsed or medically unresectable stage IV disease with non-clear cell histology (category 2A)...